Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT + Second-line Systemic Therapy in Oligoprogressive HCC
NCT06592612Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Oct 2024
- Primary completion
- Oct 2026
01
Overview
Phase 2, randomised, open-label trial (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Progression-Free Survival at 2 years. Planned start Oct 2024; status: not yet recruiting.
Beyond the preview
Go deeper on NCT06592612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06592612.